share_log

Investors in Twist Bioscience (NASDAQ:TWST) Have Seen Solid Returns of 111% Over the Past Five Years

Investors in Twist Bioscience (NASDAQ:TWST) Have Seen Solid Returns of 111% Over the Past Five Years

在过去五年里,投资Twist Bioscience(纳斯达克:TWST)的投资者获得了111%的良好回报。
Simply Wall St ·  2024/12/31 07:14

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long term Twist Bioscience Corporation (NASDAQ:TWST) shareholders would be well aware of this, since the stock is up 111% in five years. It's down 1.8% in the last seven days.

当你买入股票时,总是有可能跌幅达到100%。但好的一面是,如果你以合理的价格购买高质量公司的股票,你可以获得超过100%的收益。长期以来,Twist Bioscience Corporation(纳斯达克:TWST)的股东应该对此十分清楚,因为该股票在五年内上涨了111%。在过去的七天里,该股票下跌了1.8%。

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

现在值得关注一下公司的基本面,因为这将帮助我们判断长期股东回报是否与基础业务的表现相匹配。

Given that Twist Bioscience didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

考虑到Twist Bioscience在过去12个月内没有盈利,我们将重点关注营业收入增长,以快速了解其业务发展。无盈利公司的股东通常渴望强劲的营业收入增长。这是因为,如果营业收入增长微弱并且公司从未盈利,就很难对其可持续性充满信心。

For the last half decade, Twist Bioscience can boast revenue growth at a rate of 31% per year. That's well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 16% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes Twist Bioscience worth investigating - it may have its best days ahead.

在过去的五年里,Twist Bioscience的营业收入年增长率可达到31%。这远高于大多数未盈利公司。同时,其股价表现也确实反映了强劲的增长,因为在这段期间,该股票的股价年均增长了16%,复合增长。因此,买家似乎关注到了强劲的营业收入增长。在我们看来,这使得Twist Bioscience值得进一步调查——它可能会迎来最佳时刻。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下面的图像显示了收益和营业收入随时间的变化情况(如果点击图像,可以看到更详细的信息)。

big
NasdaqGS:TWST Earnings and Revenue Growth December 31st 2024
纳斯达克GS:TWSt 盈利和营业收入增长截至2024年12月31日

Twist Bioscience is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So it makes a lot of sense to check out what analysts think Twist Bioscience will earn in the future (free analyst consensus estimates)

Twist Bioscience是一只知名的股票,拥有众多分析师的关注,暗示着对未来增长的可见性。因此,查看分析师们对Twist Bioscience未来营收的看法是很有道理的(免费的分析师共识预估)。

A Different Perspective

不同的视角

We're pleased to report that Twist Bioscience shareholders have received a total shareholder return of 28% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 16% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Twist Bioscience , and understanding them should be part of your investment process.

我们很高兴地报告,Twist Bioscience的股东在一年内的总股东回报率达到了28%。由于一年的总股东回报率优于五年的总股东回报率(后者为每年16%),这似乎表明该股票近期表现有所改善。在最佳情况下,这可能暗示着一些真正的业务势头,意味着现在可能是深入研究的好时机。我发现,从长期来看,股价作为业务表现的代理指标是非常有趣的。但要真正获得洞察,我们还需要考虑其他信息。例如,投资风险的无处不在的幽灵。我们已经识别出Twist Bioscience的3个警告信号,理解这些信号应该是您投资过程的一部分。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你更倾向于查看其他公司——一个财务状况可能更优的公司——那么不要错过这个免费的公司列表,它们已经证明能够实现盈利增长。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文中引用的市场回报反映了当前在美国交易所上市股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发